Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Medigene to Present at Upcoming Conferences By: Medigene AG via GlobeNewswire February 19, 2024 at 08:00 AM EST Planegg/Martinsried, February 19, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will present at the 7th CAR-TCR Summit Europe taking place February 27-29, 2024, in London as well as at the East-West Biopharma Summit to be held March 4-6, 2024, in Singapore. 7th CAR-TCR Summit Europe 2024https://cartcr-europe.com/ Presentation Date: February 28, 2024, 5:30 pm local timeLocation: London, UKPresenter: Prof. Dr. Dolores Schendel, CSOPresentation: Developing effective methods to monitor, track &assess T-cell efficacy in vivo & in vitro Pre-conference workshop Date: February, 27, 2024, 1 pm local timeLocation: London, UKCo-Host: Dr. Barbara Lösch, Head, Technology & InnovationTopic: Incorporating modular control into cell therapies through receptors to enhance therapy persistence & safety Panel discussion Date: February 28, 2024, 12:30 pm local timeLocation: London, UKParticipant: Dr. Kirsty Crame, Vice President, Clinical Strategy & DevelopmentPanel topic: Selecting the right indications to ensure successful clinical outcomes Corporate presentation – East-West Biopharma Summit 2024https://conferences.biocentury.com/east-west-summit Date: March 5, 2024Location: Park Royal Collection Marina Bay, SingaporeSpeaker: Dr. Selwyn Ho, CEO Members of Medigene’s management team will be available for one-on-one meetings at the events. Please contact Dr. Fotini Vogiatzi at f.vogiatzi@medigene.com to schedule a meeting at either one of the conferences. --- end of press release --- About Medigene AG Medigene AG (FSE: MDG1) is an immuno-oncology platform company dedicated to developing differentiated T cell therapies for treatment of solid tumors. Its End-to-End Platform is built on multiple proprietary and exclusive technologies that enable the Company to generate optimal T cell receptors against both cancer testis antigens (CTAs) and neoantigens, armor and enhance these TCR-T cells to create best-in-class, differentiated T cell receptor engineered T cell (TCR-T) therapies, and optimize the drug product composition for safety, efficacy and durability. The End-to-End Platform provides product candidates for both its in-house therapeutics pipeline and partnering. Medigene’s lead TCR-T program MDG1015 is expected to receive IND/CTA approval in the second half of 2024. For more information, please visit https://medigene.com/. Medigene Pamela Keck Phone: +49 89 2000 3333 01 E-mail: investor@medigene.com In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list. Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Medigene to Present at Upcoming Conferences By: Medigene AG via GlobeNewswire February 19, 2024 at 08:00 AM EST Planegg/Martinsried, February 19, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will present at the 7th CAR-TCR Summit Europe taking place February 27-29, 2024, in London as well as at the East-West Biopharma Summit to be held March 4-6, 2024, in Singapore. 7th CAR-TCR Summit Europe 2024https://cartcr-europe.com/ Presentation Date: February 28, 2024, 5:30 pm local timeLocation: London, UKPresenter: Prof. Dr. Dolores Schendel, CSOPresentation: Developing effective methods to monitor, track &assess T-cell efficacy in vivo & in vitro Pre-conference workshop Date: February, 27, 2024, 1 pm local timeLocation: London, UKCo-Host: Dr. Barbara Lösch, Head, Technology & InnovationTopic: Incorporating modular control into cell therapies through receptors to enhance therapy persistence & safety Panel discussion Date: February 28, 2024, 12:30 pm local timeLocation: London, UKParticipant: Dr. Kirsty Crame, Vice President, Clinical Strategy & DevelopmentPanel topic: Selecting the right indications to ensure successful clinical outcomes Corporate presentation – East-West Biopharma Summit 2024https://conferences.biocentury.com/east-west-summit Date: March 5, 2024Location: Park Royal Collection Marina Bay, SingaporeSpeaker: Dr. Selwyn Ho, CEO Members of Medigene’s management team will be available for one-on-one meetings at the events. Please contact Dr. Fotini Vogiatzi at f.vogiatzi@medigene.com to schedule a meeting at either one of the conferences. --- end of press release --- About Medigene AG Medigene AG (FSE: MDG1) is an immuno-oncology platform company dedicated to developing differentiated T cell therapies for treatment of solid tumors. Its End-to-End Platform is built on multiple proprietary and exclusive technologies that enable the Company to generate optimal T cell receptors against both cancer testis antigens (CTAs) and neoantigens, armor and enhance these TCR-T cells to create best-in-class, differentiated T cell receptor engineered T cell (TCR-T) therapies, and optimize the drug product composition for safety, efficacy and durability. The End-to-End Platform provides product candidates for both its in-house therapeutics pipeline and partnering. Medigene’s lead TCR-T program MDG1015 is expected to receive IND/CTA approval in the second half of 2024. For more information, please visit https://medigene.com/. Medigene Pamela Keck Phone: +49 89 2000 3333 01 E-mail: investor@medigene.com In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.
Planegg/Martinsried, February 19, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will present at the 7th CAR-TCR Summit Europe taking place February 27-29, 2024, in London as well as at the East-West Biopharma Summit to be held March 4-6, 2024, in Singapore. 7th CAR-TCR Summit Europe 2024https://cartcr-europe.com/ Presentation Date: February 28, 2024, 5:30 pm local timeLocation: London, UKPresenter: Prof. Dr. Dolores Schendel, CSOPresentation: Developing effective methods to monitor, track &assess T-cell efficacy in vivo & in vitro Pre-conference workshop Date: February, 27, 2024, 1 pm local timeLocation: London, UKCo-Host: Dr. Barbara Lösch, Head, Technology & InnovationTopic: Incorporating modular control into cell therapies through receptors to enhance therapy persistence & safety Panel discussion Date: February 28, 2024, 12:30 pm local timeLocation: London, UKParticipant: Dr. Kirsty Crame, Vice President, Clinical Strategy & DevelopmentPanel topic: Selecting the right indications to ensure successful clinical outcomes Corporate presentation – East-West Biopharma Summit 2024https://conferences.biocentury.com/east-west-summit Date: March 5, 2024Location: Park Royal Collection Marina Bay, SingaporeSpeaker: Dr. Selwyn Ho, CEO Members of Medigene’s management team will be available for one-on-one meetings at the events. Please contact Dr. Fotini Vogiatzi at f.vogiatzi@medigene.com to schedule a meeting at either one of the conferences. --- end of press release --- About Medigene AG Medigene AG (FSE: MDG1) is an immuno-oncology platform company dedicated to developing differentiated T cell therapies for treatment of solid tumors. Its End-to-End Platform is built on multiple proprietary and exclusive technologies that enable the Company to generate optimal T cell receptors against both cancer testis antigens (CTAs) and neoantigens, armor and enhance these TCR-T cells to create best-in-class, differentiated T cell receptor engineered T cell (TCR-T) therapies, and optimize the drug product composition for safety, efficacy and durability. The End-to-End Platform provides product candidates for both its in-house therapeutics pipeline and partnering. Medigene’s lead TCR-T program MDG1015 is expected to receive IND/CTA approval in the second half of 2024. For more information, please visit https://medigene.com/. Medigene Pamela Keck Phone: +49 89 2000 3333 01 E-mail: investor@medigene.com In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.